









市場行情
/
股票
/
nasdaq-capr
/

Capricor Therapeutics Inc

CAPR

29.680USD

+0.780+2.70%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.36B總市值

虧損本益比TTM



Capricor Therapeutics Inc

29.680

+0.780+2.70%

概覽公司財務分析

概覽

公司

財務

分析

關於 Capricor Therapeutics Inc 公司

Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.

Capricor Therapeutics Inc簡介



公司代碼CAPR

公司名稱Capricor Therapeutics Inc

上市日期Jun 04, 2002

CEOMarban (Linda)

員工數量160

證券類型Ordinary Share

年結日Jun 04

公司地址10865 Road to the Cure

城市SAN DIEGO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編92121

電話13103583200

網址https://capricor.com/

公司代碼CAPR

上市日期Jun 04, 2002

CEOMarban (Linda)

Capricor Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Linda Marban, Ph.D.

President, Chief Executive Officer, Director

212.02K

+6.26%

Mr. David B. Musket

Independent Director

88.79K

Mr. Anthony Bergmann

Chief Financial Officer

8.22K

+43.68%

Dr. Michael Binks, M.D.

Chief Medical Officer

Dr. Frank I. Litvack, M.D.

Executive Chairman of the Board

Mr. George W. Dunbar, Jr.

Independent Director

Dr. Paul Auwaerter, M.D.

Independent Director

Ms. Karimah Es Sabar

Independent Director

Ms. Karen G. Krasney, J.D.

Executive Vice President, General Counsel

Dr. Philip J. (Phil) Gotwals, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Linda Marban, Ph.D.

President, Chief Executive Officer, Director

212.02K

+6.26%

Mr. David B. Musket

Independent Director

88.79K

Mr. Anthony Bergmann

Chief Financial Officer

8.22K

+43.68%

Dr. Michael Binks, M.D.

Chief Medical Officer

Dr. Frank I. Litvack, M.D.

Executive Chairman of the Board

Mr. George W. Dunbar, Jr.

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Nippon Shinyaku Co Ltd

15.51%

BlackRock Institutional Trust Company, N.A.

5.82%

The Vanguard Group, Inc.

4.83%

Geode Capital Management, L.L.C.

2.10%

State Street Investment Management (US)

1.75%

其他

69.99%

持股股東

佔比

Nippon Shinyaku Co Ltd

15.51%

BlackRock Institutional Trust Company, N.A.

5.82%

The Vanguard Group, Inc.

4.83%

Geode Capital Management, L.L.C.

2.10%

State Street Investment Management (US)

1.75%

其他

69.99%

股東類型

持股股東

佔比

Investment Advisor

16.23%

Corporation

15.51%

Investment Advisor/Hedge Fund

8.08%

Hedge Fund

4.60%

Research Firm

1.99%

Individual Investor

1.28%

Bank and Trust

0.98%

Pension Fund

0.17%

Venture Capital

0.12%

其他

51.03%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

267

14.69M

38.00%

+7.56K

2025Q3

269

14.68M

44.13%

+675.04K

2025Q2

254

13.97M

53.43%

-4.77M

2025Q1

240

18.64M

48.30%

-3.42M

2024Q4

201

17.56M

26.28%

+9.11M

2024Q3

144

8.40M

24.51%

+1.94M

2024Q2

116

6.44M

24.20%

+1.62M

2024Q1

4.82M

22.54%

-2.30M

2023Q4

4.02M

18.98%

-1.52M

2023Q3

5.55M

11.71%

+2.91M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Nippon Shinyaku Co Ltd

7.09M

15.51%

+4.94M

+230.41%

Sep 20, 2024

BlackRock Institutional Trust Company, N.A.

2.73M

5.96%

+34.47K

+1.28%

Jun 30, 2025

The Vanguard Group, Inc.

2.30M

5.02%

+41.09K

+1.82%

Jun 30, 2025

Geode Capital Management, L.L.C.

963.08K

2.11%

+61.70K

+6.85%

Jun 30, 2025

State Street Investment Management (US)

1.47M

3.21%

-376.12K

-20.41%

Jun 30, 2025

Pier Capital, LLC

367.72K

0.8%

+13.54K

+3.82%

Jun 30, 2025

Morgan Stanley & Co. LLC

463.03K

1.01%

-272.07K

-37.01%

Jun 30, 2025

Two Sigma Investments, LP

216.46K

0.47%

+91.50K

+73.23%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

0.36%

Virtus LifeSci Biotech Clinical Trials ETF

0.32%

ALPS Medical Breakthroughs ETF

0.12%

iShares Micro-Cap ETF

0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.02%

ProShares UltraPro Russell2000

0.01%

iShares Russell 2000 Growth ETF

0.01%

iShares Russell 2000 ETF

0.01%

Global X Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

iShares Neuroscience and Healthcare ETF

佔比0.36%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.32%

ALPS Medical Breakthroughs ETF

佔比0.12%

iShares Micro-Cap ETF

佔比0.05%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.02%

ProShares UltraPro Russell2000

佔比0.01%

iShares Russell 2000 Growth ETF

佔比0.01%

iShares Russell 2000 ETF

佔比0.01%

Global X Russell 2000 ETF

佔比0.01%

ProShares Hedge Replication ETF

佔比0.01%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Capricor Therapeutics Inc的前五大股東是誰？



Capricor Therapeutics Inc的前五大股東如下：
Nippon Shinyaku Co Ltd
持有股份：7.09M
佔總股份比例：15.51%。
BlackRock Institutional Trust Company, N.A.
持有股份：2.73M
佔總股份比例：5.96%。
The Vanguard Group, Inc.
持有股份：2.30M
佔總股份比例：5.02%。
Geode Capital Management, L.L.C.
持有股份：963.08K
佔總股份比例：2.11%。
State Street Investment Management (US)
持有股份：1.47M
佔總股份比例：3.21%。